rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Current clinical guidelines recommend mutation analysis for select codons in KRAS and NRAS exons 2, 3, and 4 and BRAF V600E to guide therapy selection and prognostic stratification in advanced colorectal cancer.
|
31589789 |
2020 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Circulating 25(OH)D was also inversely associated with <i>BRAF</i> V600E-positive colorectal cancer (per 25 nmol/L increment: HR, 0.71; 95% CI, 0.50-1.01).
|
30842127 |
2019 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Colorectal cancer (CRC) with the V600E mutation of B-Raf proto-oncogene serine/threonine kinase (BRAF<sup>V600E</sup>) mutation is insensitive to chemotherapy and is indicative of a poor patient prognosis.
|
30854056 |
2019 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
The absence of BRAF V600E mutation separates LLS colorectal carcinomas from MLH1-methylated colorectal carcinomas with CIMP-positive phenotype.
|
30575961 |
2019 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer.
|
30963570 |
2019 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E-Mutated Colorectal Cancer.
|
31566309 |
2019 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
The FDA-approved anti-helminthic drug rafoxanide was recently reported to antagonize the oncogenic function of the BRAF V600E mutant protein, commonly found in CRCs, as well as to inhibit the proliferation of skin cancer cells.
|
31351087 |
2019 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
MLH1 promoter methylation and V600E BRAF mutation analysis were investigated on 61 CRCs.
|
31609810 |
2019 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
BRAF V600E and SRC mutations are important molecular markers which can predict prognosis and conversion surgery in Stage IV CRC.
|
30792536 |
2019 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Overall, IHC with anti-BRAF V600E (VE1) antibody using recommended protocol with OptiView detection is optimal for detection of BRAF V600E mutation in CRC.
|
29127628 |
2019 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
<i>BRAF</i> (v-raf murine sarcoma viral oncogene homolog B1) V600E mutant colorectal cancer is associated with short survival.
|
30719102 |
2019 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
The US Food and Drug Administration approved a liquid biopsy test for EGFR-activating mutations in patients with non-small-cell lung cancer as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in non-small-cell lung cancer. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30883505 |
2019 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Previous studies have reported that rafoxanide, as an inhibitor of BRAF V600E mutant protein, inhibits the growth of colorectal cancer, multiple myeloma, and skin cancer.
|
31678170 |
2019 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Moreover, this method was proven to distinguish the BRAF V600E mutant from the wild type based on intrinsic differences by using a total of 312 CRC tissue samples paraffin-embedded, deparaffinized, and stained.
|
31208050 |
2019 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
These tumors are less likely to have microsatellite instability than CRC with a V600E BRAF mutation and often harbor a KRAS or NRAS mutation.
|
31185985 |
2019 |
rs4444235
|
|
|
0.900 |
GeneticVariation |
BEFREE |
The SNP rs4444235 at 14q22.2 interacted with regular exercise in colorectal cancer (p<sub>case-only</sub> = 2.4 × 10<sup>- 3</sup>, p<sub>case-control</sub> = 1.5 × 10<sup>- 3</sup>).
|
31849324 |
2019 |
rs6983267
|
|
|
0.900 |
GeneticVariation |
BEFREE |
We confirmed that the homozygous T/T allele of rs6983267 c-MYC indicated an interaction between dietary seaweed intake and both overall CRC and rectal cancer (CRC OR [95% CI] = 0.52 [0.34-0.81], P for interaction = 0.015; rectal cancer = 0.45 [0.25-0.79], P for interaction = 0.007, T/T carriers with high total seaweed intake vs. T/T carriers with low total seaweed intake).
|
31300834 |
2019 |
rs6983267
|
|
|
0.900 |
GeneticVariation |
BEFREE |
<i>CCAT2</i> rs6983267 was associated with the risk of CRC per</span> se (<i>p</i> < 0.01).
|
30841568 |
2019 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
BRAF inhibitor vemurafenib, and subsequent MAPK pathway inhibitors trametinib and SCH772984, significantly increased SPINK1 secretion in V600E CRC cell lines Colo205 and HT-29 with a concomitant decrease in trypsin-1 and -2 secretion.
|
29193645 |
2018 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
In this study, we explored the effect of combined use of dabrafenib, a BRAF inhibitor, and cetuximab, an EGFR inhibitor, on BRAF(V600E)-mutant CRC stem cells and its possible mechanisms.
|
29534162 |
2018 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
IHC is a suitable method to screen BRAF V600E mutation in FFPE samples of CRCs and PTCs.
|
30009773 |
2018 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Further preclinical and clinical investigations are needed to clarify the role of non-V600E mutations in CRC.
|
30463788 |
2018 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
The US FDA approved a liquid biopsy test for EGFR activating mutations in patients with non-small cell lung cancer (NSCLC) as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in NSCLC. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma.
|
30335711 |
2018 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
This study aimed to determine whether V600E mutant and wild type BRAF colorectal cancers exhibit distinct sensitivities to the dual BRAF inhibitor AZ304.
|
29755114 |
2018 |
rs113488022
|
|
|
0.900 |
GeneticVariation |
BEFREE |
Colorectal cancer (CRC) is one of the most common cancers worldwide, with 8-10% of these tumours presenting a BRAF (V600E) mutation.
|
30087414 |
2018 |